Xenon Pharmaceuticals

Yahoo Finance • 3 days ago

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of t... Full story

Yahoo Finance • last month

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializatio... Full story

Yahoo Finance • 2 months ago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializatio... Full story

Yahoo Finance • 2 months ago

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializati... Full story

Yahoo Finance • 3 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of ind... Full story

Yahoo Finance • 4 months ago

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs

Earnings Call Insights: Xenon Pharmaceuticals (XENE) Q2 2025 MANAGEMENT VIEW * Ian C. Mortimer, President and CEO, highlighted that Xenon has completed patient recruitment in its pivotal X-TOLE2 Phase III clinical trial for azetukalner... Full story

Yahoo Finance • 4 months ago

Xenon Reports Second Quarter 2025 Financial Results & Business Update

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 he... Full story

Yahoo Finance • 4 months ago

Xenon Pharma Q2 2025 Earnings Preview

* Xenon Pharma (NASDAQ:XENE [https://seekingalpha.com/symbol/XENE]) is scheduled to announce Q2 earnings results on Friday, August 11th, after market close. The consensus EPS Estimate is -$0.99 [https://seekingalpha.com/symbol/XENE/earn... Full story

Yahoo Finance • 4 months ago

Xenon to Report Q2 2025 Financial Results on August 11, 2025

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright reaffirms Buy rating on Xenon Pharmaceuticals stock at $53

Investing.com - H.C. Wainwright has reiterated its Buy rating and $53.00 price target on Xenon Pharmaceuticals (NASDAQ:XENE), highlighting the company’s leadership in ion channel drug development for CNS disorders. According to Investing... Full story

Yahoo Finance • 5 months ago

Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes

VANCOUVER/BOSTON - Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a biopharmaceutical company with a market capitalization of $2.47 billion, has been added to the Russell 3000 and Russell 2000 Indexes as part of the annual reconstitution, effec... Full story

Yahoo Finance • 5 months ago

Xenon joins Russell 3000 and Russell 2000 indexes

* Xenon Pharmaceuticals (NASDAQ:XENE [https://seekingalpha.com/symbol/XENE]) on Friday said the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at... Full story

Yahoo Finance • 5 months ago

Xenon Joins the Russell 3000® and Russell 2000® Indexes

VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story

Yahoo Finance • 5 months ago

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story

Yahoo Finance • 6 months ago

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ther... Full story

Yahoo Finance • 7 months ago

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street’s main i... Full story

Yahoo Finance • 7 months ago

Xenon to Report Q1 2025 Financial Results on May 12, 2025

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing thera... Full story

Yahoo Finance • 8 months ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficac... Full story

Yahoo Finance • 9 months ago

Xenon to Present at Stifel 2025 Virtual CNS Forum

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing the... Full story

Yahoo Finance • 9 months ago

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to ini... Full story